Publication Name	World Journal of Clinical Cases
Manuscript ID	67500
Country	China

Received	2021-05-08 03:08
Peer-Review Started	2021-05-08 03:10
To Make the First Decision
Return for Revision	2021-06-05 14:38
Revised	2021-06-17 06:46
Second Decision	2021-07-05 05:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-07-05 06:59
Articles in Press	2021-07-05 06:59
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-07-13 23:34
Typeset the Manuscript	2021-09-13 01:38
Publish the Manuscript Online	2021-09-16 08:48

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F benefits from both afatinib and osimertinib: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Yao Zhang, Ji-Qiao Shen, Lin Shao, Yan Chen, Lei Lei and Jia-Lei Wang
ORCID	Author(s) ORCID Number Yao Zhang http://orcid.org/0000-0003-1174-7049 Ji-Qiao Shen http://orcid.org/0000-0001-5547-8800 Lin Shao http://orcid.org/0000-0002-2659-4551 Yan Chen http://orcid.org/0000-0002-4474-7574 Lei Lei http://orcid.org/0000-0003-4667-0504 Jia-Lei Wang http://orcid.org/0000-0001-6944-9613
Funding Agency and Grant Number
Corresponding Author	Jia-Lei Wang, MD, Chief Physician, Department of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China. m18017312369@163.com
Key Words	Afatinib; Osimertinib; Epidermal growth factor receptor; L861Q-L833F; Non-small cell lung cancer; Case report
Core Tip	Our case revealed that both afatinib and the osimertinib + bevacizumab combination demonstrated clinical efficacy in a non-small cell lung cancer patient harboring rare epidermal growth factor receptor (EGFR) L833F-L861Q. The results provide more options for the clinical management of patients with rare EGFR compound mutations.
Publish Date	2021-09-16 08:48
Citation	Zhang Y, Shen JQ, Shao L, Chen Y, Lei L, Wang JL. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F benefits from both afatinib and osimertinib: A case report. World J Clin Cases 2021; 9(27): 8220-8225
URL	https://www.wjgnet.com/2307-8960/full/v9/i27/8220.htm
DOI	https://dx.doi.org/10.12998/wjcc.v9.i27.8220

Full Article (PDF)	WJCC-9-8220.pdf
Full Article (Word)	WJCC-9-8220.docx
CARE Checklist–2016	67500-CARE-Checklist–2016-revision.pdf
Manuscript File	67500_Auto_Edited-JPY_WangTQ.docx
Answering Reviewers	67500-Answering reviewers.pdf
Audio Core Tip	67500-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	67500-Conflict-of-interest statement.pdf
Copyright License Agreement	67500-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	67500-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	67500-Language certificate.pdf
Peer-review Report	67500-Peer-review(s).pdf
Scientific Misconduct Check	67500-Bing-Wang LL-2.png
Scientific Misconduct Check	67500-Scientific misconduct check.pdf
Scientific Editor Work List	67500-Scientific editor work list.pdf